NCT00005800View on ClinicalTrials.gov

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

January 31, 2006

Study Completion Date

May 31, 2012

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Filgrastim

DRUG

Docetaxel

DRUG

Doxorubicin

PROCEDURE

Surgery

Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Aventis Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER